Cover Image

Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review

Yun Jeong Lee,1 Hyewon Kim,1 Jiyeon Choi,1 Bo Hee Lee,1 Seok-Yong Lee2 1Department of Pharmacy, College of Pharmacy, Dankook University, Cheonan, Republic of Korea; 2Department of Pharmacy, School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea Abstract: East Asians are prone to highe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lee YJ (Author), Kim HW (Author), Choi JY (Author), Lee BH (Author), Lee SY (Author)
Format:	Book
Published:	Dove Medical Press, 2018-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
by: Cui Y, et al.
Published: (2013)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
by: Kim CO, et al.
Published: (2016)

Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects
by: Qian Zhu, et al.
Published: (2019)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
by: Cui Y, et al.
Published: (2014)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
by: Tingting Ma, et al.
Published: (2022)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018)

Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
by: Bae S, et al.
Published: (2021)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
by: Xiao-Qin Liu, et al.
Published: (2023)

A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
by: Kim E, et al.
Published: (2019)

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants
by: Susanne Johansson, et al.
Published: (2022)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
by: He X, et al.
Published: (2022)

Population pharmacokinetic-pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers
by: Steven J. Kathman, et al.
Published: (2022)

Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects
by: Oh M, et al.
Published: (2019)

Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
by: Hwang S, et al.
Published: (2021)

Low-dose versus standard-dose azithromycin for treatment of yaws
by: Lenka Mikalová, et al.
Published: (2018)

Pharmacokinetic/pharmacodynamic based dosing of ciprofloxacin in complicated urinary tract infections
by: Ana Sabo, et al.
Published: (2015)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
by: Jia Chong, et al.
Published: (2020)

Pharmacokinetics and Pharmacodynamics of YYD601, a Dual Delayed-Release Formulation of Esomeprazole, Following Single and Multiple Doses in Healthy Adult Volunteers Under Fasting and Fed Conditions
by: Lee HW, et al.
Published: (2022)

Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study
by: Hao Liang, et al.
Published: (2024)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
by: Frost C, et al.
Published: (2018)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
by: Daniele Veritti, et al.
Published: (2023)

Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
by: Jia‐yu Zhang, et al.
Published: (2024)

A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects
by: Leilei Zhu, et al.
Published: (2023)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
by: Gu N, et al.
Published: (2014)

Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
by: Yang E, et al.
Published: (2021)

Toward Model-Informed Precision Dosing for Remimazolam: A Population Pharmacokinetic-Pharmacodynamic Analysis
by: Yueting Chen, et al.
Published: (2024)

Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
by: Yaxin Fan, et al.
Published: (2022)

Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing
by: Hui-Yin Yow, et al.
Published: (2022)

Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model
by: Jurij Aguiar Zdovc, et al.
Published: (2021)

ADME, Pharmacokinetic Scaling, Pharmacodynamic and Prediction of Human Dose and Regimen of Novel Antiviral Drugs
by: Tridib Chaira, et al.
Published: (2023)

Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis
by: Aaron Heffernan, et al.
Published: (2021)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
by: Sidharta PN, et al.
Published: (2019)

Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
by: Sufeng Zhou, et al.
Published: (2023)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
by: Xu HR, et al.
Published: (2016)

Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis
by: Jason K. H. Lee, et al.
Published: (2018)

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114
by: Hikari Araki, et al.
Published: (2022)

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
by: Robert Hoerr, et al.
Published: (2022)

Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
by: Junzhen Wu, et al.
Published: (2023)

Pharmacokinetics/pharmacodynamics of glucocorticoids: modeling the glucocorticoid receptor dynamics and dose/response of commonly prescribed glucocorticoids
by: David Levitt
Published: (2024)

A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects
by: Azra Hussaini, et al.
Published: (2020)